Ranbaxy Labs Q4CY11 PAT seen at Rs 575cr

Ranbaxy Laboratories is to announce its Q4CY11. According to CNBC-TV18 estimates, the company's Q4CY11 revenues are seen up 48% to Rs 3156 crore versus Rs 2129 crore.

February 23, 2012 / 14:39 IST

Ranbaxy Laboratories is to announce its Q4CY11. According to CNBC-TV18 estimates, the company's Q4CY11 revenues are seen up 48% to Rs 3156 crore versus Rs 2129 crore.

Its EBITDA at Rs 832 crore versus Rs 230 crore.

Its OPM 26.4% versus 10.8%.

The company's PAT is seen at Rs 575 crore versus loss of Rs 97.5 crore.

Watch for:

Revenue growth due to exclusivity from Lipitor generic and authorized generic launch of Caduet

Analysts factoring in USD 200 million or Rs 980 crore from Lipitor generic

first published: Feb 23, 2012 09:37 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Ranbaxy Labs Q4CY11 PAT seen at Rs 575cr

Ranbaxy Laboratories is to announce its Q4CY11. According to CNBC-TV18 estimates, the company's Q4CY11 revenues are seen up 48% to Rs 3156 crore versus Rs 2129 crore.

RL

Subscribe to Tech Newsletters